Bergenbio ASA, commonly referred to as Bergenbio, is a pioneering biotechnology company headquartered in Norway. Founded in 2008, the company has established itself in the biopharmaceutical industry, focusing on the development of innovative cancer therapies. With a strong operational presence in Europe and North America, Bergenbio is dedicated to advancing its proprietary drug candidates, particularly its lead product, bemcentinib, which targets cancer stem cells. Bergenbio's unique approach to cancer treatment sets it apart in a competitive market, emphasising the importance of targeting the underlying mechanisms of cancer progression. The company has achieved significant milestones, including successful clinical trials and partnerships that enhance its market position. With a commitment to improving patient outcomes, Bergenbio continues to make strides in the field of oncology, positioning itself as a leader in the development of next-generation cancer therapies.
How does Bergenbio's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bergenbio's score of 10 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Bergenbio reported total carbon emissions of approximately 54,630 kg CO2e, a significant increase from about 17,540 kg CO2e in 2021. The emissions breakdown for 2022 indicates that Scope 2 emissions accounted for about 5,640 kg CO2e, while Scope 3 emissions, primarily from business travel, were approximately 49,000 kg CO2e. Despite the increase in total emissions, there are currently no disclosed reduction targets or climate pledges from Bergenbio. The company operates within a challenging industry context, where addressing carbon emissions is critical for sustainability. As Bergenbio continues to navigate its environmental impact, the focus on emissions reduction and climate commitments will be essential for aligning with global climate goals.
Access structured emissions data, company-specific emission factors, and source documents
Add to project2021 | 2022 | |
---|---|---|
Scope 1 | - | - |
Scope 2 | 5,890 | 0,000 |
Scope 3 | 11,650 | 00,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bergenbio is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.